TEKTURNA HCT
Clinical safety rating
cautionComprehensive clinical and safety monograph for TEKTURNA HCT (TEKTURNA HCT).
Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
| Metabolism | Aliskiren is primarily metabolized by CYP3A4; Hydrochlorothiazide is not metabolized and excreted unchanged in urine. |
| Excretion | Aliskiren: 78-91% unchanged in feces via biliary excretion, <2.4% in urine. Hydrochlorothiazide: ≥95% renal, 50-75% unchanged. |
| Half-life | Aliskiren: terminal half-life 24-31 hours (accumulation supports once-daily dosing). Hydrochlorothiazide: 6-15 hours (correlates with duration of action). |
| Protein binding | Aliskiren: 47-51% (albumin). Hydrochlorothiazide: 40-68% (albumin). |
| Volume of Distribution | Aliskiren: 0.65-2.3 L/kg (extensive tissue distribution due to lipophilicity). Hydrochlorothiazide: 3-7 L/kg (distributes into erythrocytes). |
| Bioavailability | Aliskiren: 2-5% oral (1.6-2.8% at 300 mg). Hydrochlorothiazide: 65-70% oral. |
| Onset of Action | Aliskiren: 2 hours (oral). Hydrochlorothiazide: 2 hours (oral). |
| Duration of Action | Aliskiren: >24 hours (additional effect at 2 weeks). Hydrochlorothiazide: 6-12 hours (antihypertensive effect up to 24 hours). |
| Molecular Weight | Aliskiren hemifumarate: 609.8 Da; hydrochlorothiazide: 297.74 Da |
Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min/1.73m2. For GFR 30-59 mL/min/1.73m2: no dose adjustment required, but monitor serum potassium and creatinine. Discontinue if progressive oliguria or acute renal failure occurs. |
| Liver impairment | Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: use with caution; no specific dose guidelines. |
| Pediatric use | Safety and efficacy not established in pediatric patients less than 18 years of age. |
| Geriatric use | Elderly patients may be more sensitive to hypotension and electrolyte imbalances. Start at the lowest dose (150/12.5 mg) and titrate cautiously. Monitor renal function and electrolytes regularly. |
| 1st trimester | Use in first trimester is associated with fetal toxicity including oligohydramnios, fetal renal dysfunction, and skull ossification defects. Risk is lower than second and third trimesters but still exists. Use only if no alternative. |
| 2nd trimester | Contraindicated in second trimester due to high risk of fetal renal impairment, oligohydramnios, and adverse neonatal outcomes. Discontinue as soon as pregnancy is detected. |
| 3rd trimester | Contraindicated in third trimester because of severe fetal and neonatal risks including anuria, hypotension, and death from oligohydramnios and renal failure. |
Clinical note
Comprehensive clinical and safety monograph for TEKTURNA HCT (TEKTURNA HCT).
| Placental transfer | Aliskiren and hydrochlorothiazide both cross the placenta in humans. Aliskiren has been detected in fetal plasma and amniotic fluid; hydrochlorothiazide crosses and may cause electrolyte disturbances in the fetus. |
| Breastfeeding | No data on presence in breast milk; due to potential for adverse effects on the nursing infant, such as hypotension and renal impairment, manufacturer recommends avoiding breastfeeding during therapy. |
| Lactation Rating | Avoid |
| Teratogenic Risk | First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossification defects. Second and third trimesters: Exposure is associated with fetal hypotension, anuria, renal failure, oligohydramnios, skull hypoplasia, and death. Hydrochlorothiazide: Crosses the placenta; risk of electrolyte disturbances, jaundice, and thrombocytopenia in the newborn. Generally avoid in pregnancy, especially second and third trimesters. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, serum electrolytes, and urine output. Perform fetal ultrasound to assess amniotic fluid volume, renal anatomy, and skull development, especially after first trimester exposure. Monitor newborn for hypotension, oliguria, hyperkalemia, and electrolyte disturbances. |
| Fertility Effects | Limited data. No specific adverse effects on fertility reported for aliskiren or hydrochlorothiazide. However, uncontrolled hypertension may affect fertility; control with alternative antihypertensives if pregnancy is planned. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to aliskiren, hydrochlorothiazide, or any sulfonamide-derived drugs (hydrochlorothiazide is a sulfonamide derivative)AnuriaConcomitant use with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors in patients with diabetes mellitus (increases risk of renal impairment, hypotension, and hyperkalemia)Pregnancy (second and third trimesters; avoid in first trimester if possible)
| Precautions | Avoid use in pregnancy (especially 2nd and 3rd trimesters) due to fetal toxicity; discontinue immediately if pregnancy occurs., Not recommended with ACE inhibitors or ARBs in patients with diabetes or renal impairment (CrCl < 60 mL/min) due to increased risk of renal dysfunction, hyperkalemia, and hypotension., Symptomatic hypotension may occur, especially in volume-depleted patients; correct volume depletion before use., Electrolyte imbalances: monitor serum potassium (risk of hyperkalemia), sodium, and magnesium; hydrochlorothiazide may cause hypokalemia, hyponatremia, and hypomagnesemia., Renal impairment: monitor renal function; may cause acute renal failure; contraindicated with CrCl < 30 mL/min for hydrochlorothiazide component., Angioedema may occur; discontinue if develops. |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and potassium-containing salt substitutes. Limit sodium intake to assist antihypertensive effect. Grapefruit juice may reduce aliskiren absorption; avoid concurrent consumption. |
| Clinical Pearls | Tekturna HCT is a fixed-dose combination of aliskiren (renin inhibitor) and hydrochlorothiazide (thiazide diuretic). Avoid use in pregnancy (category D). Monitor renal function and serum electrolytes, especially potassium and sodium, as aliskiren can increase potassium and HCTZ can cause hypokalemia. Contraindicated with concomitant use of ARBs or ACE inhibitors in patients with diabetes or renal impairment (eGFR <60 mL/min/1.73 m²). Assess for hypotension, especially in volume-depleted patients. Max antihypertensive effect may take 2-4 weeks. |
| Patient Advice | Do not take if pregnant or planning to become pregnant; use effective contraception. · Avoid potassium supplements, salt substitutes, or high-potassium foods without consulting your doctor. · Take exactly as prescribed; do not skip doses or double up. · May cause dizziness; avoid driving until you know how the medication affects you. · Drink adequate fluids to prevent dehydration, especially in hot weather or with exercise. · Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion. · Avoid alcohol as it may increase blood pressure-lowering effects and dizziness. |
Loading safety data…